Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Athersys Is Soaring Today

By Maxx Chatsko - Updated Apr 23, 2019 at 4:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stem cell pioneer announced an update with its most important collaborator.

What happened

Shares of Athersys (ATHX 4.92%) jumped more than 18% today after the company announced that a collaboration partner has enrolled the first patient in a clinical trial in Japan. Healios is evaluating a product derived from MultiStem, the novel stem cell platform developed by Athersys, as a potential treatment for pneumonia-induced acute respiratory distress syndrome (ARDS).

The clinical trial will evaluate the safety and efficacy of the drug candidate in 30 patients total, with the number of ventilator-free days serving as the primary endpoint. It follows positive results from a phase 1/2 trial that were announced earlier this year.

As of 3:22 p.m. EDT, the stock had settled to an 18.2% gain.

A businessman tossing stacks of dollar bills in the air.

Image source: Getty Images.

So what

Athersys reported $24.3 million in revenue in 2018 (and an operating loss of $25 million), which was by far the highest level of revenue achieved in the last five years. Most of it was derived from the collaboration with Healios. The pair are working together to co-develop MultiStem in multiple applications, including ARS and ischemic stroke. The latter indication is being explored in an ongoing phase 3 trial.

While investors are excited with the company's maturing pipeline and committed international partner, they cannot overlook the fact that Athersys has failed to commercialize MultiStem for the last decade. Shares have lost value in the most recent one-year, three-year, and five-year periods.

Now what

At the very least, Athersys is well funded. The company exited February 2019 with $51.5 million in cash and cash equivalents. It can sell up to $100 million in common stock through the first quarter of 2021 to support operations, which is great for keeping the business afloat but not so great for shareholders. Maybe the small-cap stem cell pioneer can finally get a product to the market in the years ahead, but investors should remain grounded about the company's prospects. This remains a risky stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Athersys, Inc. Stock Quote
Athersys, Inc.
ATHX
$0.19 (4.92%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.